Hemab Therapeutics Holdings COAG Ratios (2025-2026)

NASDAQ COAG
$40.86 +1.48 (+3.76%)
At close: Nov 13, 2026 · 4:00 PM EST
Reported Financials

Hemab Therapeutics Holdings Quarterly Ratios

Periods 7 quarters
Latest Sep 2026

Hemab Therapeutics Holdings ratios data for the quarter ended Sep 2026. These financial ratios cover 7 quarters of results from Mar 2025 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

RatiosRatios Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Efficiency
Assets AverageAssets Avg. 185.02M321.52M455.25M
Equity AverageEquity Avg. -122.21M-135.31M-149.74M-167.32M-187.63M127.83M441.77M
Valuation
Price to BookP/B 2.433.36
Enterprise Value 648.53M1,010.93M
Market Capitalization 1,105.99M1,441.17M
Return Ratios
Return on Capital Employed [ROCE]ROCE -42.65%-26.83%-21.82%
Return on Assets [ROA]ROA -39.10%-26.74%-21.11%
Return on Equity [ROE]ROE -67.27%-21.76%

Hemab Therapeutics Holdings Ratios API

Pull Hemab Therapeutics Holdings's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=COAG&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY